title: Dose‑dependent effect of lysozyme upon Candida albicans biofilm.
abstract: The present study investigated the in vitro effect of lysozyme (0-1,000 µg/ml) on Candida albicans (C. albicans) biofilm development. Investigations were conducted on C. albicans ATCC 10231 and on 10 clinical isolates from dentures. Strains were cultured aerobically at 37˚C in Sabouraud broth. Yeast growth was evaluated by turbidimetry. Biofilm biomass was quantified on a polystyrene support by crystal violet staining and on acrylic surfaces by counts of colony forming units. Lysozyme affected biofilm formation to a greater extent than it affected growth. For the ATCC 10231 reference strain, lysozyme acted as a biofilm promotor on polystyrene at the highest concentration tested (1,000 µg/ml, non‑physiological). When the reference strain was investigated on acrylic resin support, lysozyme acted as a significant biofilm promotor on rough resin, but less on smooth resin. The attached biomass in the presence of physiological concentrations of lysozyme (10‑30 µg/ml) was significantly decreased compared with the hypothetical value of 100% using a one‑sample t‑test, but a comparison between the different lysozyme conditions using analysis of variance and post hoc tests did not reveal significant differences. In 10 wild strains, different patterns of biofilm formation on polystyrene were observed in the presence of lysozyme. Some strains, characterized by large amounts of biofilm formation in the presence of 1,000 µg/ml lysozyme, were poor biofilm producers at low concentrations of lysozyme. In contrast, some strains that were poor biofilm producers with a high lysozyme concentration were more inhibited by low concentrations of lysozyme. The present study emphasizes the need to develop strategies for biofilm control based on in vitro experiments, and to implement these in clinical trials prior to approval of hygiene products enriched with exocrine proteins, such as lysozyme. Further studies will extend these investigations to other Candida species, and to fungi and bacteria present in oral biofilms.
authors.affiliation: Laboratory of Physiology and Pharmacology, Université Libre de Bruxelles, B‑1070 Brussels, Belgium.
authors.forename: Sarra
authors.initials: S
authors.lastname: Sebaa
authors.affiliation: Laboratory of Physiology and Pharmacology, Université Libre de Bruxelles, B‑1070 Brussels, Belgium.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Hizette
authors.affiliation: Laboratory of Antibiotics Antifungals: Physico‑Chemistry, Synthesis and Biological Activity, University of Aboubekr Belkaïd‑Tlemcen, Tlemcen 13000, Algeria.
authors.forename: Zahia
authors.initials: Z
authors.lastname: Boucherit-Otmani
authors.affiliation: Laboratory of Physiology and Pharmacology, Université Libre de Bruxelles, B‑1070 Brussels, Belgium.
authors.forename: Philippe
authors.initials: P
authors.lastname: Courtois
mesh_terms: D000818:Animals; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development*; D002176:Candida albicans / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D009113:Muramidase / Q000494:pharmacology*
chemical_list: D009113:Muramidase